P2.04-09 Driver Mutations are Associated with Distinct Patterns of Response to Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
Open accessIntegrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Broad studies that connect tumor genomic changes to cytotoxic and targeted drug sensitivity have revealed many pharmacogenomic interactions in NSCLC and other cancers.
“Large-scale efforts aimed at linking tumor genomic alterations with sensitivity to cytotoxic and targeted therapies have uncovered a wealth of pharmacogenomic interactions in NSCLC and other cancer types149–152.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [149]
Cited by
Sorted by citations
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019 · see citing works
Self-citationEGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins
Remón, J., Hendriks, L. E. L., Cardona, A. F., & Besse, B. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102105 · Cited by 127 · see citing works
- Authors
- Negrao, M., Reuben, A., Robichaux, J., Le, X., Nilsson, M., Elamin, Y., Wu, C., Zhang, J., Landry, L. L., Roarty, E., Rinsurongkawong, W., Swisher, S., Simon, G., Futreal, P. A., Glisson, B., Zhang, J., & Heymach, J.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 13
- Issue
- 10
- Pages
- S733-S734
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2898591419
- Cited by
- 2
- References
- 0
- Citations by year
- 2020: 1 · 2019: 1
- FWCI
- 0.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- non-small cell lung cancer, immune checkpoint blockade, PD-1/PD-L1 inhibitors, driver mutations, EGFR exon 20 mutations, BRAF mutation, lung adenocarcinoma, progression-free survival, treatment response, rare mutations, predictive biomarkers, co-occurring mutations
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
